Selective 11β-HSD1 Inhibitors for Metabolic Syndrome
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for metabolic syndromes caused by excessive glucocorticoids, such as non-insulin dependent diabetes and obesity, face limitations due to nonselective inhibition of 11β-HSD1 and 11β-HSD2 enzymes, leading to side effects like hypokalemia and hypertension.
Innovation Solution
Development of novel picolinamide and pyrimidine-4-carboxamide compounds with selective inhibitory activity for 11β-HSD1 enzymes, which are used to prevent, regulate, and treat diseases related to glucocorticoid regulation, including metabolic syndromes, by inhibiting the conversion of glucocorticoids into active forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective inhibitors of 11β-HSD1 and 11β-HSD2 (e.g., carbenoxolone) are used to treat metabolic syndromes, then glucocorticoid conversion is inhibited, but side effects such as hypokalemia and hypertension occur due to nonselective inhibition
Solution Approach 1:
The invention segments the inhibition action into two distinct parts: selective inhibition of 11β-HSD1 enzyme while leaving 11β-HSD2 enzyme unaffected. This is achieved through the specific molecular structure of the compound (formula 1) which has been designed to fit the 11β-HSD1 active site selectively, thereby providing therapeutic efficacy without the harmful side effects associated with nonselective inhibition
Solution Approach 2:
The compound exhibits different inhibitory properties at different target sites: it shows strong inhibitory activity against 11β-HSD1 (with IC50 values in the nanomolar range) while showing negligible inhibition against 11β-HSD2. This local differentiation in inhibitory quality allows the drug to achieve therapeutic benefits in tissues expressing 11β-HSD1 (liver, adipose, brain) without affecting tissues where 11β-HSD2 is predominant (kidney, salivary glands)
2Object-affected harmful factors
If selective inhibitors of 11β-HSD1 are developed to avoid side effects, then therapeutic safety is improved, but the complexity of drug development and synthesis increases
Solution Approach 1:
The invention achieves selectivity by modifying key structural parameters of the inhibitor molecule. The compound (formula 1) contains specific substituents at defined positions (R1-R7, L, X, Y, Z) that can be varied to optimize both selectivity and potency. By systematically changing these molecular parameters, the inventors identified structures that selectively inhibit 11β-HSD1 while maintaining reasonable synthetic accessibility through established organic chemistry methods
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit 11β-HSD1 enzymes, providing therapeutic benefits for metabolic syndromes like type 2 diabetes, obesity, and hypertension without the side effects associated with nonselective inhibition, thereby improving insulin sensitivity and glucose tolerance.
Implementation Method 1
selective inhibitory activity for an 11β-HSD1 enzyme... inhibit the conversion of glucocorticoids into the active type to suppress the action of glucocorticoids in the tissue
Data Source
AI summary
Provided are picolinamide and pyrimidine-4-carboxamide compounds, a method for preparing the same, a pharmaceutical composition containing the same, and a medical use using the compound as an agent for preventing, regulating, and treating diseases related to regulation of glucocorticoids by using selective inhibitory activity of the compound for an 11β-HSD1 enzyme. The picolinamide and pyrimidine-4-carboxamide compounds of the present invention are selective inhibitors of human-derived 11β-HSD1 enzymes, and are useful in an agent for preventing, regulating, and treating diseases related to glucocorticoid regulation in which human-derived 11β-HSD1 enzymes are involved, for example, metabolic syndromes such as, type 1 and type 2 diabetes, diabetes later complications, latent autoimmune diabetes adult (LADA), insulin tolerance syndromes, obesity, impaired glucose tolerance (IGT), impaired fasting glucose (IFG), damaged glucose tolerance, dyslipidemia, atherosclerosis, hypertension, etc.